LC PRS: Factors Affecting Participation in Lung Cancer Genomic Testing (H-50553)
Introduction: Lung cancer is a leading cause of cancer-related deaths in the United States, with high incidence and death rates among Non-Hispanic blacks and Non-Hispanic whites. Blood tests have recently been developed to identify individuals who may be at increased risk for developing lung cancer (i.e., polygenic risk scores) and to detect the presence of lung cancer at a very early stage (biomarker testing) based on a person’s genetic markers. This study seeks to develop a clearer understanding of factors that may influence the clinical uptake of such tests should they become commercially available.
Purpose: The goal of the study is to inform development of initiatives to improve people’s knowledge, access, and participation in lung cancer genomic and biomarker testing as these tests become more commercially available. Toward this end, we are asking healthcare providers and patients for their perspectives on individual and system factors that could affect clinical uptake of polygenic testing for lung cancer risk and biomarker testing to detect early lung cancer.
Design: The LC PRS Study comprises two parts.
- Part 1 involves a brief survey and qualitative interview of African-American and Non-Hispanic White patients recruited from the outpatient clinics at BSLMC and BTGH.
- Part 2 involves a one-time survey and qualitative interview with healthcare providers from BSLMC and BTGH
You may qualify to take part in this study if you are an adult over the age of 18 and are fluent in English. For their time and effort, participants will receive a $20 gift card upon completion of the survey and a $30 gift card upon completion of the interview.
Grant funding from National Cancer Institute.